Payment overview · 2025
General Payments
$1,079.79
79 reported records · 18 companies
Healthcare provider profile · identity verified
Hollis J Cotton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1437194792
Verified facts
What the public records show
CMS Open Payments records show Hollis J Cotton, MD received $1,079.79 in general payments during 2025 across 79 reported records.
Amgen Inc. accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $164.92 | 15.3% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $164.58 | 15.2% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $153.33 | 14.2% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $137.11 | 12.7% | 9 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $79.34 | 7.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.77 | 5.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $52.71 | 4.9% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $42.18 | 3.9% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $42.00 | 3.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.77 | 3.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.79 | 2.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.82 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.76 | 1.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.06 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.00 | 1.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.57 | 1.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.23 | 1.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.85 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,079.79 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $147.17 | 16 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $130.83 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $129.58 | 14 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $114.06 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $112.38 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $93.36 | 5 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $79.34 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.77 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $52.71 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.52 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $42.18 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.68 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.47 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.77 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.79 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.73 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $6.28 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $6.28 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $3.27 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $3.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 192 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
192 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
192 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 551 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 367 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 346 | 93 |
| Omeprazole | Omeprazole | 314 | 87 |
| Losartan Potassium | Losartan Potassium | 283 | 81 |
| Gabapentin | Gabapentin | 253 | 42 |
| Montelukast Sodium | Montelukast Sodium | 221 | 66 |
| Lisinopril | Lisinopril | 217 | 68 |
| Furosemide | Furosemide | 216 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 209 | 58 |
| Alprazolam | Alprazolam | 204 | 34 |
| Eliquis | Apixaban | 192 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 53 |
| Lorazepam | Lorazepam | 161 | 26 |
| Simvastatin | Simvastatin | 159 | 41 |
| Meloxicam | Meloxicam | 158 | 41 |
| Glimepiride | Glimepiride | 148 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 46 |
| Trazodone Hcl | Trazodone Hcl | 146 | 47 |
| Prednisone | Prednisone | 139 | 80 |
| Metformin Hcl | Metformin Hcl | 138 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 137 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 26 |
| Valsartan | Valsartan | 131 | 37 |
| Celecoxib | Celecoxib | 119 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 32 |
| Sertraline Hcl | Sertraline Hcl | 116 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 25 |
| Potassium Chloride | Potassium Chloride | 89 | 30 |
| Naproxen | Naproxen | 87 | 23 |
| Famotidine | Famotidine | 86 | 23 |
| Allopurinol | Allopurinol | 84 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 29 |
| Terazosin Hcl | Terazosin Hcl | 82 | 24 |
| Carvedilol | Carvedilol | 81 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 21 |
| Ozempic | Semaglutide | 80 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 20 |
| Tramadol Hcl | Tramadol Hcl | 69 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 25 |
| Donepezil Hcl | Donepezil Hcl | 66 | 18 |
| Atenolol | Atenolol | 65 | 17 |
| Cefdinir | Cefdinir | 65 | 54 |
| Doxazosin Mesylate | Doxazosin Mesylate | 65 | 18 |
| Alendronate Sodium | Alendronate Sodium | 62 | 16 |
| Buspirone Hcl | Buspirone Hcl | 62 | 14 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 15 |
| Metformin Hcl Er | Metformin Hcl | 60 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 16 |
| Synthroid | Levothyroxine Sodium | 58 | 13 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Jardiance | Empagliflozin | 51 | 12 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Dutasteride | Dutasteride | 48 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 12 |
| Clonidine Hcl | Clonidine Hcl | 45 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 34 |
| Azithromycin | Azithromycin | 43 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 12 |
| Diazepam | Diazepam | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | 12 |
| Temazepam | Temazepam | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 34 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 12 |
| Meclizine Hcl | Meclizine Hcl | 37 | 23 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 31 |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 28 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 14 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 14 |
| Topiramate | Topiramate | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 12 |
| Finasteride | Finasteride | 17 | suppressed |
| Oxazepam | Oxazepam | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,079.79 · 79 records | Amgen Inc. | ABRYSVO, AIRSUPRA, CAMZYOS, COMIRNATY, CREON, ELIQUIS, FFRct, FREESTYLE LIBRE 3, GEMTESA, HORIZANT, KRYSTEXXA, LEQVIO, LINZESS, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error